Symbols / RVPH
RVPH Chart
About
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 26.86M |
| Enterprise Value | 13.27M | Income | -22.76M | Sales | — |
| Book/sh | 0.05 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -1.34 | PEG | — |
| P/S | — | P/B | 4.89 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 1.35 |
| Current Ratio | 1.39 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.44 | EPS next Y | -0.17 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-30 | ROA | -130.48% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 116.85M |
| Shs Float | 111.60M | Short Float | 21.16% | Short Ratio | 5.62 |
| Short Interest | — | 52W High | 1.60 | 52W Low | 0.23 |
| Beta | 0.04 | Avg Volume | 5.06M | Volume | 3.06M |
| Target Price | $4.50 | Recom | Strong_buy | Prev Close | $0.24 |
| Price | $0.23 | Change | -4.21% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.50
Mean price target
2. Current target
$0.23
Latest analyst target
3. DCF / Fair value
$-2.90
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.23
Low
$1.50
High
$16.00
Mean
$4.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-05 | main | Chardan Capital | Buy → Buy | $2 |
| 2025-12-23 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-12-23 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-11-19 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-10-28 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-09-29 | init | Chardan Capital | — → Buy | $2 |
| 2025-09-19 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-09-15 | main | Benchmark | Speculative Buy → Speculative Buy | $7 |
| 2025-08-18 | reit | Roth Capital | Buy → Buy | $3 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-08-15 | main | Maxim Group | Buy → Buy | $2 |
| 2025-06-27 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-06-03 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-05-20 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-04-24 | main | D. Boral Capital | Buy → Buy | $8 |
| 2025-04-01 | main | D. Boral Capital | Buy → Buy | $8 |
| 2025-01-22 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-01-21 | main | D. Boral Capital | Buy → Buy | $15 |
| 2025-01-10 | up | Maxim Group | Hold → Buy | $7 |
- FDA recommends another large trial for new schizophrenia drug - Stock Titan ue, 23 Dec 2025 08
- Why Did RVPH Stock Crash 50% Today? - Stocktwits ue, 23 Dec 2025 08
- Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026 - Yahoo Finance Sun, 11 Jan 2026 08
- Is RVPH Positioned For NDA Submission In Schizophrenia By 2026? - RTTNews Mon, 01 Dec 2025 08
- Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025 - TechStock² Wed, 24 Dec 2025 08
- New Analyst Forecast: $RVPH Given $2.0 Price Target | RVPH Stock News - Quiver Quantitative Wed, 19 Nov 2025 08
- Reviva Pharmaceuticals Granted Nasdaq Extension to Regain Compliance - TipRanks Fri, 23 Jan 2026 08
- Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High - Seeking Alpha ue, 16 Dec 2025 08
- Reviva’s Schizophrenia Bet Pits Huge Upside Against Harsh Risks - Finimize Sat, 29 Nov 2025 02
- Small-Cap CNS Drug Developer Reviva Takes Stage at Roth Conference to Discuss Blockbuster Potential - Stock Titan hu, 02 Oct 2025 07
- RVPH: Brilaroxazine Poster Presentations - Yahoo Finance Mon, 24 Nov 2025 08
- New Analyst Forecast: $RVPH Given 'Speculative Buy' Rating | RVPH Stock News - Quiver Quantitative Mon, 15 Sep 2025 07
- Why Is Reviva Pharmaceuticals Stock (RVPH) Down 40% Today? - TipRanks Fri, 19 Sep 2025 07
- Reviva (NASDAQ: RVPH) posts net loss of $4.0M; targets 2026 NDA submission - Stock Titan hu, 13 Nov 2025 08
- RVPH sets vote on 515M authorized shares and reverse split plan - Stock Titan ue, 04 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 150.71K | -50.24K | -40.89K | 429.58K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -30.60M | -38.97M | -28.03M | -10.10M |
| TotalUnusualItems | 717.64K | -239.22K | -194.71K | 1.59M |
| TotalUnusualItemsExcludingGoodwill | 717.64K | -239.22K | -194.71K | 1.59M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -29.92M | -39.26M | -28.26M | -8.52M |
| ReconciledDepreciation | 0.00 | |||
| EBITDA | -29.88M | -39.21M | -28.23M | -8.51M |
| EBIT | -29.88M | -39.21M | -28.23M | -8.51M |
| NetInterestIncome | 342.87K | 364.69K | 182.80K | -2.41K |
| InterestExpense | 18.50K | 33.73K | 2.41K | |
| InterestIncome | 361.37K | 398.41K | 182.80K | |
| NormalizedIncome | -30.49M | -39.07M | -28.11M | -9.68M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -29.92M | -39.26M | -28.26M | -8.52M |
| TotalExpenses | 30.80M | 39.50M | 28.23M | 10.10M |
| TotalOperatingIncomeAsReported | -30.80M | -39.50M | -28.23M | -10.10M |
| DilutedAverageShares | 33.15M | 23.80M | 19.52M | 14.79M |
| BasicAverageShares | 33.15M | 23.80M | 19.52M | 14.79M |
| DilutedEPS | -0.90 | -1.65 | -1.25 | -0.58 |
| BasicEPS | -0.90 | -1.65 | -1.25 | -0.58 |
| DilutedNIAvailtoComStockholders | -29.92M | -39.26M | -28.26M | -8.52M |
| NetIncomeCommonStockholders | -29.92M | -39.26M | -28.26M | -8.52M |
| NetIncome | -29.92M | -39.26M | -28.26M | -8.52M |
| NetIncomeIncludingNoncontrollingInterests | -29.92M | -39.26M | -28.26M | -8.52M |
| NetIncomeContinuousOperations | -29.92M | -39.26M | -28.26M | -8.52M |
| TaxProvision | 19.51K | 16.95K | 20.78K | 6.00K |
| PretaxIncome | -29.90M | -39.24M | -28.24M | -8.52M |
| OtherIncomeExpense | 556.73K | -104.94K | -194.71K | 1.59M |
| OtherNonOperatingIncomeExpenses | -160.92K | 134.28K | ||
| GainOnSaleOfSecurity | 717.64K | -239.22K | -194.71K | 1.59M |
| NetNonOperatingInterestIncomeExpense | 342.87K | 364.69K | 182.80K | -2.41K |
| TotalOtherFinanceCost | -182.80K | 2.41K | ||
| InterestExpenseNonOperating | 18.50K | 33.73K | 2.41K | |
| InterestIncomeNonOperating | 361.37K | 398.41K | 182.80K | |
| OperatingIncome | -30.80M | -39.50M | -28.23M | -10.10M |
| OperatingExpense | 30.80M | 39.50M | 28.23M | 10.10M |
| ResearchAndDevelopment | 22.91M | 31.42M | 22.87M | 4.85M |
| SellingGeneralAndAdministration | 7.89M | 8.08M | 5.36M | 5.25M |
| GeneralAndAdministrativeExpense | 7.89M | 8.08M | 5.36M | 5.25M |
| OtherGandA | 7.89M | 8.08M | 5.36M | 5.25M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 46.58M | 27.92M | 20.45M | 14.43M |
| ShareIssued | 46.58M | 27.92M | 20.45M | 14.43M |
| TotalDebt | 458.15K | |||
| TangibleBookValue | 812.57K | 5.72M | 8.39M | 28.69M |
| InvestedCapital | 1.27M | 5.72M | 8.39M | 28.69M |
| WorkingCapital | 81.86K | 6.53M | 8.96M | 29.06M |
| NetTangibleAssets | 812.57K | 5.72M | 8.39M | 28.69M |
| CommonStockEquity | 812.57K | 5.72M | 8.39M | 28.69M |
| TotalCapitalization | 812.57K | 5.72M | 8.39M | 28.69M |
| TotalEquityGrossMinorityInterest | 812.57K | 5.72M | 8.39M | 28.69M |
| StockholdersEquity | 812.57K | 5.72M | 8.39M | 28.69M |
| RetainedEarnings | -164.27M | -134.35M | -95.09M | -66.83M |
| AdditionalPaidInCapital | 165.08M | 140.07M | 103.49M | 95.52M |
| CapitalStock | 4.66K | 2.79K | 2.04K | 1.44K |
| CommonStock | 4.66K | 2.79K | 2.04K | 1.44K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 14.69M | 17.98M | 10.53M | 2.72M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 89.01K | 806.65K | 567.44K | 372.73K |
| DerivativeProductLiabilities | 89.01K | 806.65K | 567.44K | 372.73K |
| CurrentLiabilities | 14.60M | 17.18M | 9.96M | 2.34M |
| CurrentDebtAndCapitalLeaseObligation | 458.15K | |||
| CurrentDebt | 458.15K | |||
| OtherCurrentBorrowings | 458.15K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 635.59K | 958.61K | 564.65K | |
| PayablesAndAccruedExpenses | 13.51M | 16.22M | 9.40M | 2.34M |
| CurrentAccruedExpenses | 7.22M | 12.37M | 5.88M | 1.84M |
| Payables | 6.28M | 3.85M | 3.52M | 509.58K |
| AccountsPayable | 6.28M | 3.85M | 3.52M | 509.58K |
| TotalAssets | 15.50M | 23.70M | 18.92M | 31.40M |
| TotalNonCurrentAssets | 819.72K | 0.00 | 0.00 | 0.00 |
| NonCurrentPrepaidAssets | 819.72K | 0.00 | ||
| CurrentAssets | 14.68M | 23.70M | 18.92M | 31.40M |
| OtherCurrentAssets | 666.43K | 254.64K | 403.82K | 1.72M |
| PrepaidAssets | 540.60K | 78.30K | 403.82K | 1.72M |
| CashCashEquivalentsAndShortTermInvestments | 13.48M | 23.37M | 18.52M | 29.69M |
| CashAndCashEquivalents | 13.48M | 23.37M | 18.52M | 29.69M |
| CashEquivalents | 12.20M | 22.21M | ||
| CashFinancial | 1.27M | 1.16M | 29.69M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -33.54M | -28.32M | -18.96M | -10.67M |
| RepaymentOfDebt | -518.75K | -667.50K | 0.00 | |
| IssuanceOfDebt | 976.90K | 667.50K | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 23.19M | 27.49M | 7.77M | 31.50M |
| InterestPaidSupplementalData | 18.50K | 30.62K | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 3.42K | 19.75K | 16.48K | 2.40K |
| EndCashPosition | 13.48M | 23.37M | 18.52M | 29.69M |
| BeginningCashPosition | 23.37M | 18.52M | 29.69M | 8.76M |
| ChangesInCash | -9.89M | 4.85M | -11.17M | 20.93M |
| FinancingCashFlow | 23.65M | 33.17M | 7.79M | 31.60M |
| CashFlowFromContinuingFinancingActivities | 23.65M | 33.17M | 7.79M | 31.60M |
| ProceedsFromStockOptionExercised | 149.00 | 5.68M | 18.97K | 98.48K |
| NetCommonStockIssuance | 23.19M | 27.49M | 7.77M | 31.50M |
| CommonStockIssuance | 23.19M | 27.49M | 7.77M | 31.50M |
| NetIssuancePaymentsOfDebt | 458.15K | 0.00 | 0.00 | 0.00 |
| NetShortTermDebtIssuance | 458.15K | 0.00 | 0.00 | |
| ShortTermDebtPayments | -518.75K | -667.50K | 0.00 | |
| ShortTermDebtIssuance | 976.90K | 667.50K | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| OperatingCashFlow | -33.54M | -28.32M | -18.96M | -10.67M |
| CashFlowFromContinuingOperatingActivities | -33.54M | -28.32M | -18.96M | -10.67M |
| ChangeInWorkingCapital | -4.54M | 7.28M | 8.93M | -702.17K |
| ChangeInPayablesAndAccruedExpense | -2.84M | 7.21M | 7.62M | 1.01M |
| ChangeInAccruedExpense | -5.14M | 6.88M | 4.61M | 1.51M |
| ChangeInInterestPayable | 0.00 | |||
| ChangeInPayable | 2.29M | 328.84K | 3.01M | -498.46K |
| ChangeInAccountPayable | 2.29M | 328.84K | 3.01M | -498.46K |
| ChangeInPrepaidAssets | -1.69M | 70.89K | 1.31M | -1.71M |
| OtherNonCashItems | 39.93K | |||
| StockBasedCompensation | 1.63M | 3.41M | 176.74K | 106.71K |
| DepreciationAmortizationDepletion | 0.00 | |||
| DepreciationAndAmortization | 0.00 | |||
| Depreciation | 0.00 | |||
| OperatingGainsLosses | -717.64K | 239.22K | 194.71K | -1.59M |
| GainLossOnInvestmentSecurities | -717.64K | 239.22K | 194.71K | -1.59M |
| NetIncomeFromContinuingOperations | -29.92M | -39.26M | -28.26M | -8.52M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RVPH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|